目的 探討絞股藍(lán)總苷片聯(lián)合依折麥布治療高脂血癥的臨床療效。方法 選取2020年12月—2022年12月武漢市中醫(yī)醫(yī)院收治的136例高血脂癥患者，按照數(shù)字隨機(jī)法將患者分對(duì)照組（68例）和治療組（68例）。對(duì)照組患者口服依折麥布片，10 mg/次，1次/d。在對(duì)照組的基礎(chǔ)上，治療組口服絞股藍(lán)總苷片，3片/次，3次/d。兩組連續(xù)服藥15 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時(shí)間，血脂總膽固醇（TC）、三酰甘油（TG）、高密度脂蛋白膽固醇（HDL-C）和低密度脂蛋白膽固醇（LDL-C）水平，血管內(nèi)皮功能內(nèi)皮素-1（ET-1）、一氧化氮（NO）、血管假性血友病因子（vWF）和白細(xì)胞介素6（IL-6）水平。結(jié)果 治療后，治療組臨床有效率為98.53%，明顯高于對(duì)照組（85.29%，P＜0.05）。治療后，治療組癥狀好轉(zhuǎn)時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組患者血脂TG、TC和LDL-C水平明顯降低，而HDL-C水平明顯升高（P＜0.05），且治療組血脂水平明顯好于對(duì)照組（P＜0.05）。治療后，兩組血管內(nèi)皮功能ET-1、vWF、IL-6水平明顯降低，而NO水平明顯升高（P＜0.05），且治療組ET-1、vWF、IL-6和NO水平均明顯好于對(duì)照組（P＜0.05）。結(jié)論 絞股藍(lán)總苷片聯(lián)合依折麥布治療高脂血癥可促進(jìn)臨床癥狀有效改善，降低高血脂癥狀態(tài)，對(duì)內(nèi)皮功能調(diào)節(jié)增強(qiáng)。

Objective To investigate the effects of Jiaogulan ZongdaiTablets and ezhemai in treatment of hyperlipidemia. Methods Patients (136 cases) with hyperlipidemia in Wuhan Hospital of Traditional Chinese Medicine from December 2020 to December 2022 were divided into control group (68 cases) and treatment group (68 cases) according to numerical random method. Patients in the control group were po administered with Ezetimibe Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Jiaogulan Zongdai Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the levels of blood lipids TG, TC, LDL-C and HDL-C, the levels of vascular endothelial function indexes ET-1, vWF, IL-6 and NO in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.53%, which was significantly higher than that of the control group (85.29%, P< 0.05). After treatment, the improvement time of symptom in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of blood lipids TG, TC and LDL-C in two groups were significantly decreased, while the level of HDL-C were significantly increased (P < 0.05), the level of blood lipid in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the levels of ET-1, vWF and IL-6 of vascular endothelial function were significantly decreased, while the level of NO was significantly increased in two groups (P< 0.05), and the levels of ET-1, vWF, IL-6 and NO in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The synergistic treatment of ezhemai and Jiaogulan Zongdai Tablets is effective in treatment of hyperlipidemia, which can effectively improve clinical symptoms, reduce the state of hyperlipidemia, and enhance the regulation of endothelial function.

湖北省科技廳科技計(jì)劃項(xiàng)目（2018CFB707）